Literature DB >> 19015363

International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.

Roger J M Brüggemann1, Daan J Touw, Rob E Aarnoutse, Paul E Verweij, David M Burger.   

Abstract

An international interlaboratory proficiency testing program for the measurement of antifungal drugs was initiated in 2007. This first round was limited to azole antifungals: fluconazole, itraconazole and hydroxyitraconazole, voriconazole, and posaconazole. The results demonstrate the need for and utility of an ongoing proficiency testing program to further improve the analytical methods for routine patient management and clinical research.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19015363      PMCID： PMC2612190          DOI： 10.1128/AAC.00901-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  International interlaboratory quality control program for measurement of antiretroviral drugs in plasma.

Authors:  Rob E Aarnoutse; Corrien P W G M Verweij-van Wissen; Eleonora W J van Ewijk-Beneken Kolmer; Eveline W Wuis; Peter P Koopmans; Yechiel A Hekster; David M Burger
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.

Authors:  Jacqueline A H Droste; Rob E Aarnoutse; Peter P Koopmans; Yechiel A Hekster; David M Burger
Journal:  J Acquir Immune Defic Syndr       Date:  2003-03-01       Impact factor: 3.731

3.  Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Authors:  Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 5.  Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

Authors:  Jeannina Smith; David Andes
Journal:  Ther Drug Monit       Date:  2008-04       Impact factor: 3.681

6.  An evaluation of analytic goals for assays of drugs: a College of American Pathologists Therapeutic Drug Monitoring Survey Study.

Authors:  B W Steele; E Wang; G E Palomaki; G G Klee; R J Elin; S J Soldin; D L Witte
Journal:  Arch Pathol Lab Med       Date:  2001-06       Impact factor: 5.534

7.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079
  7 in total
  15 in total

1.  Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.

Authors:  Bertrand Rochat; Andres Pascual; Benoît Pesse; Frédéric Lamoth; Dominique Sanglard; Laurent A Decosterd; Jacques Bille; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

3.  Relevance of timing for determination of posaconazole plasma concentrations.

Authors:  Werner J Heinz; Janina Zirkel; Anna Kuhn; Diana Schirmer; Ulrike Lenker; Daniela Keller; Hartwig Klinker
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

4.  Simultaneous quantitation of five triazole anti-fungal agents by paper spray-mass spectrometry.

Authors:  Christine L Skaggs; Greta J Ren; El Taher M Elgierari; Lillian R Sturmer; Run Z Shi; Nicholas E Manicke; Lindsey M Kirkpatrick
Journal:  Clin Chem Lab Med       Date:  2020-04-28       Impact factor: 3.694

5.  Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratories.

Authors:  Robin DiFrancesco; Susan L Rosenkranz; Charlene R Taylor; Poonam G Pande; Suzanne M Siminski; Richard W Jenny; Gene D Morse
Journal:  Ther Drug Monit       Date:  2013-10       Impact factor: 3.681

6.  Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.

Authors:  Eleftheria Mavridou; Roger J M Bruggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

7.  Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole.

Authors:  Saskia Kuipers; Roger J M Brüggemann; Ruud G L de Sévaux; John P F A Heesakkers; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

8.  Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation.

Authors:  Joshua Wolf; Monica A Slavin
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

9.  Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Authors:  Eleftheria Mavridou; Roger J M Brüggemann; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

Review 10.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.